天下彩免费资料大全|曾夫人资料_曾夫人论坛 科技有限公司坐落于北京亦庄经济开发区,拥有1880平米GMP实验室和办公室。公司从美国马里兰大学引进的“IHV-DC”技术突破了细胞免疫抗癌技术的瓶颈,极有可能为人类彻底攻克癌症打开希望之门;世界著名病毒学家、生物学家Robert Gallo对技术评价说:这是一项伟大的发现,有划时代意义,它有可能开启治疗癌症和病毒的新篇章。
        公司将基于IHV-DC技术逐步以下方面开展研发和产业化经营活动:(一)肿瘤过继性细胞免疫治疗:逐步开展针对肺癌、乳腺癌、前列腺癌等实体肿瘤的临床和新药申报。(二)病毒感染性疾病治疗:针对乙肝、艾滋病及其它病毒感染性疾病的免疫治疗;针对乙型肝炎引起的肝癌免疫治疗;(三)肿瘤新抗原个性化疗法,基于永生化DC细胞的抗癌疫苗设计应用,预防癌症扩散和复发。(四)永生化DC细胞株存储服务。
        目前,惠大生物与中国人民解放军总医院(301医院)正在开展IHV-DC技术治疗非小细胞肺癌的临床实验,该技术中国唯一,世界领先。
        

    Situated in the Beijing Economic-Technological Development Area, Huida Biotechnology is an enterprise with a registered capital of RMB350 million. This enterprise engages in the research and exploitation of cellular immunotherapy. Cellular immunotherapy kills tumors in a patient through the “transformation” of the immunocytes into an “immunocyte corps” and transferring them into the patient’s body in order to prevent the transfer or recrudescence of tumors, prolong survival time and improve the quality of life of the patient. In 2013, cellular immunotherapy was selected to be the “Breakthrough of the Year” by Science. From then on, cellular immunotherapy has drawn extensive attention in the academic world.

    The Company has engaged in strategic cooperation with the Institute of Human Virology  of the School of Medicine, University of Maryland, with the goal to 
industrialize the immunotherapy in China.
 
    The IHV of the University of Maryland is one of the foremost authorities on HIV basic research, R&D of HIV drugs and vaccines, animal experiments, as well as clinical diagnosis and treatment in the world; and especially on cellular research. Co-founded by Robert Gallo, MD, director of the of the IHV, and IHV’s Chinese professors and directors, Huida Biotechnology has committed itself to offering both safe and effective cellular immunotherapy-based solutions to Chinese patients.